Among patients with Parkinson disease or parkinsonism undergoing a 30-day multidisciplinary intensive rehabilitation treatment (MIRT), consumption of a twice-daily whey protein-based nutritional supplement enriched with leucine and vitamin D preserved muscle mass and improved lower extremity function.
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
In patients with Parkinson disease (PD), vitamin D levels are significantly correlated with falls and some nonmotor symptoms.
While AZD0530 is reasonably safe and well tolerated in participants with mild Alzheimer disease (AD), it has no significant effect on cerebral metabolic decline nor on clinical or biomarker measures in AD.
Three trajectories of respiratory function have been identified in patients with amyotrophic lateral sclerosis.
Focal epilepsy may accelerate widespread progressive cortical thinning to a greater degree than that observed in normal aging.
More frequent social contact during midlife is associated with a lower dementia risk and better cognitive trajectories.
Engaging in regular physical activity and taking active measures to reduce vascular risk may have a synergistic effect in delaying the progression of Alzheimer disease.
According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.
Plasma β-amyloid (Aβ)42/Aβ40 corresponds with amyloid positron emission tomography (PET) status.